Growth and Innovation in the U.S. Market

Lupin’s specialty business in the U.S. was established in 2003 with the reintroduction of SUPRAX (cefixime) oral suspension. Vinita Gupta was the President of Lupin Pharmaceuticals Inc. at the time and daughter of Desh Bandhu Gupta, Lupin Limited’s founder. Vinita has guided Lupin’s U.S. business with a sense of deep conviction, leveraging a lifetime of familiarity with the pharmaceutical industry. Her vision was to grow a specialty brand business that launches innovative new products to address unmet medical needs.

Since its founding, Lupin’s U.S. brand business has been driven by that vision. We have marketed a range of products across therapeutic categories, including ANTARA® (fenofibrate) and METHERGINE® (methylergonovine maleate), as well as launching InspiraChamber® (valved holding chamber) and, most recently, SOLOSEC® (secnidazole). While these brands treat a wide range of medical conditions, they have one important commonality: they are part of a sincere effort to broaden the treatment landscape for the benefit of patients and providers alike.

SOLOSEC®: The Latest Addition to Our Specialty Portfolio

Our specialty business remains committed to Vinita Gupta‘s vision, who now acts as the CEO of Lupin. The launch of SOLOSEC® in 2018 demonstrates that commitment. SOLOSEC® is an innovative single-dose, granule-based treatment for bacterial vaginosis in adult women, offering features that set it apart from a crowded market.

Lupin has built a dedicated team to educate healthcare professionals (HCPs) and patients about SOLOSEC®. We promote to specialists in women’s health, including obstetrician/ gynecologists, nurse practitioners, physicians’ assistants and pharmacists. Our dedication is emblematic of our commitment to growth and continual innovation.

solosec oral granules packaging
Learn More
Learn About Our Strategic Plan